Luc is a Managing Partner at DROIA Ventures since early 2020, a VC firm focused on genetic diseases and oncology with currently over €500 million under management. He currently serves as DROIA’s representative on the Boards of Montis Biosciences (Chairman), Vaderis, Volastra, Quralis, Vico Therapeutics (Chairman) and Alesta (Chairman). Prior to joining the VC world, Luc was an executive for over 20 years in several biotech companies. He was a co-founder of VICO Therapeutics and acted as their CEO till 2020. He is also a co-founder of Pharvaris. He was Chief Executive Officer of Tusk Therapeutics from May 2015 until its acquisition by Roche in September 2018. He joined Tusk from Prosensa Holding N.V. where he served as Chief Business Officer and Senior Vice President of Business Development for a period of seven years until its acquisition by BioMarin Pharmaceutical Inc. Earlier in his career, he served as Vice President of Business Development at TiGenix, Director Business Development at Methexis Genomics, and a consultant at Arthur D. Little. Luc holds a Pharm.D. degree and a postgraduate degree in business economics from the University of Leuven (Belgium) and an MBA from Vlerick Management School (Belgium). Luc also serves on the Board of Directors of Cascador Health (where is a co-founder) and a not-for-profit organization.